Broadly neutralizing antibodies against HIV-1 and concepts for application

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial

(2022) Henning Gruell et al.   Lancet Microbe

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption

(2021) Denise C. Hsu et al.   PLoS Pathogens

Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants

(2021) Elizabeth J McFarland et al.   JOURNAL OF INFECTIOUS DISEASES

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

(2021) Lawrence Corey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates

(2021) Lars Hangartner et al.   Science Translational Medicine

Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth

(2021) Deniz Cizmeci et al.   eLife

Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials

(2021) Brian Moldt et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Effective high-throughput isolation of fully human antibodies targeting infectious pathogens

(2021) Lutz Gieselmann et al.   Nature Protocols

Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer

(2021) William D. Tolbert et al.   mBio

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

(2021) Kathryn E. Stephenson et al.   NATURE MEDICINE

Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity

(2021) Benjamin S. Goldberg et al.   mBio

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

(2020) Philipp Schommers et al.   CELL

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth

(2020) Krishna M. Roskin et al.   NATURE IMMUNOLOGY

Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity

(2020) Julia Niessl et al.   NATURE MEDICINE

Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity

(2020) Mariya B. Shapiro et al.   Nature Communications

Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody

(2020) Mangaiarkarasi Asokan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo

(2020) Pengfei Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies

(2020) David A. Garber et al.   Nature Communications

Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies

(2020) Marina Tuyishime et al.   JOURNAL OF CLINICAL INVESTIGATION

SIV infection duration largely determines broadening of neutralizing antibody response in macaques

(2020) Fan Wu et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia

(2020) Yoshiaki Nishimura et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Relationships between Neutralization, Binding, and ADCC of Broadly Neutralizing Antibodies against Reservoir HIV

(2020) Yanqin Ren et al.   JOURNAL OF VIROLOGY

A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite

(2020) Sonu Kumar et al.   Science Advances

Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth

(2020) Ryan S. Roark et al.   SCIENCE

Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial

(2019) Frances H Priddy et al.   Lancet HIV

Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression

(2019) José M. Martinez-Navio et al.   IMMUNITY

Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual

(2019) Shelly J. Krebs et al.   IMMUNITY

An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes

(2019) Adam S. Dingens et al.   IMMUNITY

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope

(2019) Till Schoofs et al.   IMMUNITY

Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

(2019) Marina Caskey et al.   NATURE MEDICINE

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users

(2019) Zelda EULER et al.   Viruses-Basel

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Trevor A Crowell et al.   Lancet HIV

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

(2019) Amarendra Pegu et al.   Cell Host & Microbe

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study

(2019) Yehuda Z. Cohen et al.   PLoS One

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01

(2019) Dora Pinto et al.   Cell Host & Microbe

Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants

(2019) Coleen K Cunningham et al.   JOURNAL OF INFECTIOUS DISEASES

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

(2019) Jon M. Steichen et al.   SCIENCE

An MPER antibody neutralizes HIV-1 using germline features shared among donors

(2019) Lei Zhang et al.   Nature Communications

Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates

(2019) Reda Rawi et al.   Scientific Reports

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

(2019) Martin R Gaudinski et al.   Lancet HIV

High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity

(2019) Ian Setliff et al.   CELL

Anti‐ HIV ‐1 antibodies trigger non‐lytic complement deposition on infected cells

(2019) Jérémy Dufloo et al.   EMBO REPORTS

Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses

(2018) Mohammad Mohseni Sajadi et al.   CELL

A Neutralizing Antibody Recognizing Primarily N -Linked Glycan Targets the Silent Face of the HIV Envelope

(2018) Tongqing Zhou et al.   IMMUNITY

The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen

(2018) Colin Havenar-Daughton et al.   Science Translational Medicine

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

(2018) Martin R. Gaudinski et al.   PLOS MEDICINE

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses

(2018) Roger D. Kouyos et al.   NATURE

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

(2018) Pilar Mendoza et al.   NATURE

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

(2018) Yotam Bar-On et al.   NATURE MEDICINE

Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques

(2018) Matthew S. Parsons et al.   JOURNAL OF CLINICAL INVESTIGATION

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

(2018) Erica N. Borducchi et al.   NATURE

Early antibody therapy can induce long-lasting immunity to SHIV

(2017) Yoshiaki Nishimura et al.   NATURE

Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time

(2017) Anna Hake et al.   PLoS Computational Biology

Determinants of HIV-1 broadly neutralizing antibody induction

(2016) Peter Rusert et al.   NATURE MEDICINE

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

(2016) T. Schoofs et al.   SCIENCE

An integrated map of HIV genome-wide variation from a population perspective

(2015) Guangdi Li et al.   Retrovirology

Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection

(2013) Peter Hraber et al.   AIDS

Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure

(2013) Ya-Chi Ho et al.   CELL

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

(2011) J. F. Scheid et al.   SCIENCE

Enhanced antibody half-life improves in vivo activity

(2010) Jonathan Zalevsky et al.   NATURE BIOTECHNOLOGY

Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

(2009) M. D. Simek et al.   JOURNAL OF VIROLOGY

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

(2009) Johannes F. Scheid et al.   NATURE